Jump to content

Lulizumab pegol

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 15:30, 28 February 2016 (molar weight unit in g/mol (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Lulizumab pegol
Monoclonal antibody
Type?
SourceHumanized
Targetglycoprotein CD28
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
Chemical and physical data
FormulaC552H859N149O164S4
Molar mass52 kg/mol g·mol−1

Lulizumab pegol[1] is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]

This drug was developed by Bristol-Myers Squibb.

References

  1. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lulizumab_pegol&oldid=707384775"